Drugs / BMS-906024
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01653470 | Oct 2012 → May 2017 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01363817 | Sep 2011 → Feb 2018 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01292655 | Mar 2011 → Jun 2017 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-906024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01292655 ↗ |
| Action | Inhibit | “BMS-906024 (Notch inhibitor)” NCT01292655 ↗ |
| Route | Intravenous | “BMS-906024 solution intravenously as specified” NCT01292655 ↗ |